Sionna Therapeutics Showcases Innovative Preclinical Data
Sionna Therapeutics, Inc. (Nasdaq: SION), a biopharmaceutical company located in Waltham, is on a transformative journey to enhance the treatment landscape for cystic fibrosis (CF). The company's mission focuses on developing novel medicines aimed at normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In their upcoming oral presentation, they will showcase preclinical data that assesses the exciting potential of their innovative therapies.
Details of the Presentation
During the European Cystic Fibrosis Society’s 48th conference in Milan, scheduled from June 4-7, 2025, Sionna will present their findings on combination therapies that explore the efficacy of Sionna’s NBD1 stabilizers, SION-451 and SION-719, alongside their CFTR modulators, galicaftor (SION-2222) and SION-109.
What to Expect from the Presentation
The presentation is titled "Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of ?F508-CFTR" and is expected to bring forth substantial insights into CF treatment. Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President of Discovery Research at Sionna Therapeutics, will lead this session, showcasing how these combinations hold the potential to significantly improve clinical outcomes for individuals living with cystic fibrosis.
Key Aspects of Sionna's Research
Sionna's approach is centered on the development of therapies that stabilize the CFTR protein's nucleotide-binding domain 1 (NBD1). This focus stems from more than ten years of research by the company’s founders, which indicates that addressing the NBD1 can lead to transformative improvements in treatment effectiveness and overall quality of life for patients affected by CF.
Innovative Solutions for CF Patients
The potential of Sionna’s therapies lies in their tailored design to correct the defects caused by the F508del genetic mutation, a common mutation among CF patients. This genetic anomaly interferes with the normal function of the CFTR protein, leading to serious respiratory issues and other complications. Sionna is also actively developing complementary CFTR modulators intended to work in concert with their NBD1 stabilizers to further enhance CFTR functionality.
Commitment to Transparency and Communication
As part of their commitment to transparency, Sionna Therapeutics utilizes its Investor Relations website to share significant company updates and material information. Investors are encouraged to keep track of these developments through ongoing press releases, SEC filings, and public presentations. This proactive approach ensures that stakeholders remain well-informed about the company's progress and strategies related to cystic fibrosis treatments.
Media and Investor Contacts
For further inquiries regarding their research, Sionna Therapeutics has made contact persons available for media and investor relations:
Media Contact:
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact:
Juliet Labadorf
ir@sionnatx.com
Frequently Asked Questions
What is the focus of Sionna Therapeutics?
Sionna Therapeutics aims to revolutionize cystic fibrosis treatment through innovative medicines that stabilize CFTR function.
When and where is Sionna presenting their findings?
Sionna will present during the European Cystic Fibrosis Society’s conference in Milan from June 4-7, 2025.
What are the main therapies being discussed?
The discussion will focus on NBD1 stabilizers and how they synergize with CFTR modulators to correct CFTR function.
Who will present Sionna's findings?
Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President, will lead the presentation at the conference.
How can investors stay updated on Sionna’s progress?
Investors can monitor the Sionna Investor Relations website and other updates for information on the company’s activities and disclosures.
